Bruker Adds to In Vivo Imaging Offerings
A Carestream spokesperson told IBO that the sale involves all of Carestream’s preclinical in vivo imaging systems. He said the firm is divesting its digital molecular imaging segment because it provided only 1% of Carestream’s revenue and that the sale “aligns the digital in vivo product line with a company with a primary focus on this market segment.” Carestream’s small animal imaging product line utilizes MicroPET/SPECT and optical technologies, which Bruker currently does not offer.
Bruker Adds to In Vivo Imaging Offerings
Rochester, NY and Billerica, MA 9/21/12—Bruker has entered into an agreement to purchase the preclinical in vivo imaging equipment product portfolio and related assets of Carestream’s Molecular Imaging business. The purchase price was not disclosed. The majority of employees at the business will be offered the opportunity to join Bruker. “We believe that Carestream’s optical molecular imaging product line will complement our other preclinical solutions, presently consisting of magnetic resonance imaging (MRI), magnetic particle imaging (MPI) and X-ray micro computed tomography (microCT),” stated Dr. Werner Maas, president of Bruker BioSpin. Carestream will retain the other assets of its Molecular Imaging business, including the life science X-ray film business, and the Gel Logic and Image Station in vitro imaging equipment products. However, new production of the Gel Logic and Image Station products will be discontinued. The company will continue to operate its life science X-ray film business. The purchase is expected to close in the next several weeks.